Falls Prevention: Gait-Synchronized Vibration System

Overview

The purpose of this study is to develop an abnormal gait detection algorithm and a vibratory stimulation system on a lower limb to improve gait stability and prevent falls. The investigators want to detect, assess and communicate fall risk indicators obtained via the shoe sensors, and assess effectiveness of a gait synchronized vibration system to the plantar surface in reducing fall risk.The system consists of a gait measurement module, an abnormal gait detection module, and a vibratory stimulation module.

Full Title of Study: “Falls Prevention Using a Gait-Synchronized Vibration System”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 30, 2018

Detailed Description

Forty (40) Individuals with decreased confidence in ambulatory scores (<80%) as per the Activities Specific Balance Confidence questionnaire, will undergo functional assessments for visual (Snellen chart, Humphrey Visual Field Testing, Gaze Stabilization test, depth perception evaluation), vestibular (Dizziness Handicap Inventory, Head Thrust test) and proprioceptive (Balance Master, Berg Balance Scale, Joint Position Sense) impairments, to evaluate factors which might contribute to increased falls risk. Participants will be asked to walk return for a second visit and to walk with a shoe sensor and gait synchronized vibratory stimulus under conditions of (1) Baseline performance on the Six Minute Walk test (2) Performance on the Six Minute Walk test and Dynamic Gait Index without vibratory stimulus (3) Performance on the Six Minute Walk test and Dynamic Gait Index with vibratory stimulus.

Interventions

  • Device: Gait Synchronized Vibration System
    • A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.

Arms, Groups and Cohorts

  • Experimental: PD Shoe
    • 40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.

Clinical Trial Outcome Measures

Primary Measures

  • Test the efficacy of a wearable shoe sensor to detect initiation of abnormal gait patterns that increase the likelihood of falls
    • Time Frame: 1 hour; The entire protocol for testing the PD shoe is expected to be less than 2hours.
    • Investigators will use pearson’s correlation tests on gait variables (cadence, velocity, stride and step lengths) on Dynamic Gait Index that correlate with visual, proprioceptive and vestibular impairments and functional indicators of fall risk (e.g., Berg Balance Scale, Dynamic Gait Index, Activities Specific Balance Confidence questionnaire, Dizziness Handicap Inventory, Gaze Stabilization and Head Thrust Test) to determine variables that indicate an increased likelihood of falls.

Secondary Measures

  • Assess effectiveness of a gait synchronized vibration system to the plantar surface in reducing fall risk.
    • Time Frame: 1 hour; The entire protocol for testing the PD shoe is expected to be less than 2hours.
    • Investigators will measure the change in gait parameters (cadence, velocity, stride and step lengths) and performance on the Dynamic Gait Index with and without vibratory stimulus.

Participating in This Clinical Trial

Inclusion Criteria

1. Individuals aged 65 or greater. 2. Low balance confidence (scores <80%) on the ABC Balance Confidence Scale 3. Berg Balance Scale (BBS) scores between 21 (moderate fall risk) and 56 (low fall risk). Exclusion Criteria:

1. No internal implantable device (i.e. Pacemaker, Intrathecal Baclofen Pump) 2. Significant painful arthritis (scores 15 or greater) as per the Short Arthritis Assessment Scale. 3. Significant cognitive deficits (scores <2) as per Ascertain Dementia 8 (AD8) questionnaire. 4. Significant visual field deficits as per the Humphrey Visual Field Analysis or significant uncorrected visual acuity deficits as per the Snellen Eye Chart. 5. Current treatment with anticoagulation medication 6. Parkinson's Disease or known Peripheral Neuropathy 7. Limitations to exercise related to cardiac, neurological or pulmonary diseases 8. Orthostatic hypotension 9. Severe osteoporosis defined by fracture history, BMD by DEXA (T score more than 2.5 standard deviations below controls in the last 2 years), or height loss of more than 3 cm 10. Current treatment with corticosteroids or aromatase inhibitor 11. Current treatment with seizure medication

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • NYU Langone Health
  • Collaborator
    • Columbia University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Preeti Raghavan, M.D., Principal Investigator, New York University Medical School

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.